India API Quality-Inspection Team In China Still Not In Place
This article was originally published in PharmAsia News
Executive Summary
India, the target of foreign regulator efforts to ensure the safety of locally produced drugs, has yet to station its own quality-inspection team in China, supplier of much of the raw materials on which India drug makers rely.